What Researchers Did
Researchers reviewed treatment outcomes and performed a radiomic analysis for 48 patients with radiation necrosis who were treated with oral pentoxifylline and vitamin E.
What They Found
Of the patients, 43.8% showed improvement in radiation necrosis, 18.8% showed no change, and 25% experienced worsening on imaging after starting treatment. The median time to response assessment was 3.17 months. Patients with multiple lesions treated with stereotactic radiosurgery were less likely to improve (p = 0.037), and dexamethasone use was not associated with an improved response (p = 0.471). A machine learning model was successfully developed to predict treatment response.
What This Means for Canadian Patients
This study suggests that pentoxifylline and vitamin E may offer a treatment option for some Canadian patients experiencing radiation necrosis, a serious complication of radiation therapy. While not universally effective, the development of a predictive model could help clinicians identify which patients are most likely to benefit. For those whose condition worsens, the abstract notes that hyperbaric oxygen therapy (HBOT) is among the alternative treatments considered.
Canadian Relevance
This study covers radiation necrosis, a condition for which hyperbaric oxygen therapy (HBOT) is sometimes used as a treatment option for progressing patients, as noted in the abstract. No direct Canadian authors or institutions were identified.
Study Limitations
This was a retrospective study conducted at a single institution with a relatively small sample size of 48 patients, which may limit the generalizability of its findings.